Table 4: Mantel-Haenszel analysis between CHADVASc, HAS-BLED, GBS, Oakland scores with timing of anticoagulation resumption and our three primary outcomes.
Day of restart |
(1) |
(2) |
(3) |
(4) |
(5) |
(6) |
(7) |
(8) |
1 |
0.9 |
0.28 |
0.87 |
0.27 |
0.449 |
0.04 |
0.197 |
0.59 |
2 |
N/A |
0.65 |
0.7 |
0.53 |
0.916 |
0.822 |
0.29 |
0.42 |
3 |
0.65 |
N/A |
N/A |
N/A |
N/A |
0.833 |
0.79 |
0.37 |
4 |
0.39 |
N/A |
N/A |
N/A |
N/A |
0.62 |
0.5 |
0.32 |
5 |
N/A |
N/A |
N/A |
N/A |
N/A |
0.388 |
0.09 |
0.22 |
6 |
N/A |
N/A |
N/A |
N/A |
N/A |
0.08 |
0.28 |
0.28 |
7 |
N/A |
0.59 |
0.755 |
0.68 |
0.342 |
0.14 |
0.68 |
0.34 |
8 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
0.15 |
9 |
N/A |
N/A |
N/A |
N/A |
N/A |
0.15 |
N/A |
N/A |
10 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
>10 |
0.5 |
0.36 |
0.26 |
0.36 |
N/A |
0.26 |
0.36 |
N/A |
(1) CHADVASc vs. thrombotic events; (2) CHADVASc vs. mortality events; (3) HAS-BLED vs. Mortality events; (4) GBS vs. Mortality events; (5) OAKLAND vs. Mortality events; (6) HAS-BLED vs. Bleeding events; (7) GBS vs. Bleeding event; (8) OAKLAND vs. Bleeding events